COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS

COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS

FIELD: biotechnology.SUBSTANCE: invention relates to the field of biotechnology, specifically to a method for the treatment or slowing down the development of FolR1-expressing cancer in an individual. The method includes injection to an individual of a bispecific antigen-binding molecule binding to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: TSIPPELIUS Alfred, SHRAJNER Jens, KLYAJN Kristian, TOMMEN Daniela, KARANIKAS Vaios, UMANA Pablo
Format: Patent
Sprache:eng ; rus
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:FIELD: biotechnology.SUBSTANCE: invention relates to the field of biotechnology, specifically to a method for the treatment or slowing down the development of FolR1-expressing cancer in an individual. The method includes injection to an individual of a bispecific antigen-binding molecule binding to CD3 and FolR1 and an antagonist binding to the PD-1 axis.EFFECT: obtaining compounds for the treatment of cancer.30 cl, 40 dwg, 49 tbl, 50 ex Изобретение относится к области биотехнологии, конкретно к способу лечения или замедления развития экспрессирующего FolR1-рака у индивидуума. Способ включает введение индивидууму биспецифической антигенсвязывающей молекулы, связывающейся с CD3 и FolR1, и антагониста, связывающегося с осью PD-1. 2 н. и 28 з.п. ф-лы, 40 ил., 49 табл., 50 пр.